Skip to main content
OpenTrials
Completed

NCT Number: NCT01952392

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–130 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Paris, France

About this study

AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.

No Exclusion Criteria.

Treatment and study plan

Primary outcomes

  1. Medical information

    Time frame: At baseline visit

    History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors

  2. Drug exposure

    Time frame: Current

    Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.

  3. Drug exposure

    Time frame: Recent

    Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.

  4. Drug exposure

    Time frame: Past

    Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.

Secondary outcomes

  1. Other medical events of interest

    Time frame: During follow-up (up to 12 months)

    rMI, stroke, bleeding, death

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Acronym: AReMIS

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Sep 30, 2013
Registry last updated
Feb 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.